Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11421370rdf:typepubmed:Citationlld:pubmed
pubmed-article:11421370lifeskim:mentionsumls-concept:C0019196lld:lifeskim
pubmed-article:11421370lifeskim:mentionsumls-concept:C0009462lld:lifeskim
pubmed-article:11421370lifeskim:mentionsumls-concept:C1282910lld:lifeskim
pubmed-article:11421370lifeskim:mentionsumls-concept:C0010362lld:lifeskim
pubmed-article:11421370lifeskim:mentionsumls-concept:C0013715lld:lifeskim
pubmed-article:11421370pubmed:issue5-6lld:pubmed
pubmed-article:11421370pubmed:dateCreated2001-6-25lld:pubmed
pubmed-article:11421370pubmed:abstractTextThe prevalence of antibody to hepatitis C virus (anti-HCV) was determined in a cross-sectional survey in a village in Upper Egypt. Exposure and demographic characteristics were obtained through a questionnaire. Antibody to hepatitis C virus was assessed using a second generation enzyme immunoassay, and the presence of HCV RNA was tested using a reverse transcriptase-polymerase chain reaction. Collection of blood samples was targeted at those > or = 5 years old, and obtained from 62.8%. This report describes the community, the HCV infection characteristics of the subjects, and evaluates some factors associated with presence of anti-HCV. Of the 6,031 participants, 522 (8.7%) were anti-HCV positive. Prevalence was higher among males than females (11.3% versus 6.5%; P < 0.001). It was greater among those > 30 years of age than among those < or = 30 years of age (20.0% versus 3.6%; P < 0.001). Those who were less educated, farmed, provided health care, and were currently married had a significantly higher anti-HCV prevalence than those who were not; however, these associations were not significant after adjusting for age. Although active infections with Schistosoma haematobium were not associated with anti-HCV, a history of past infection was (age-adjusted risk ratio [RR] = 2.1, 95% confidence interval [CI] = 1.8, 2.4); 134 persons who had a history of receiving parenteral anti-schistosomal therapy had a higher age-adjusted RR (3.0; 95% CI = 2.5, 3.7) for anti-HCV than those who did not. Hepatitis C virus RNA was detected in 62.8% of the anti-HCV positive subjects, without significant variation by age, gender, education, or marital status. The prevalence of anti-HCV in Upper Egypt is high, albeit lower than in Lower Egypt, with continuing but limited transmission indicated by the lower prevalence in residents < or = 30 years old.lld:pubmed
pubmed-article:11421370pubmed:languageenglld:pubmed
pubmed-article:11421370pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11421370pubmed:citationSubsetAIMlld:pubmed
pubmed-article:11421370pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11421370pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11421370pubmed:statusMEDLINElld:pubmed
pubmed-article:11421370pubmed:issn0002-9637lld:pubmed
pubmed-article:11421370pubmed:authorpubmed-author:StricklandG...lld:pubmed
pubmed-article:11421370pubmed:authorpubmed-author:WattsSSlld:pubmed
pubmed-article:11421370pubmed:authorpubmed-author:NafehM AMAlld:pubmed
pubmed-article:11421370pubmed:authorpubmed-author:ShehataMMlld:pubmed
pubmed-article:11421370pubmed:authorpubmed-author:SallaiEElld:pubmed
pubmed-article:11421370pubmed:authorpubmed-author:Abdel-HamidMMlld:pubmed
pubmed-article:11421370pubmed:authorpubmed-author:AnwarWWlld:pubmed
pubmed-article:11421370pubmed:authorpubmed-author:MedhatAAlld:pubmed
pubmed-article:11421370pubmed:authorpubmed-author:FixA DADlld:pubmed
pubmed-article:11421370pubmed:authorpubmed-author:SwifeeYYlld:pubmed
pubmed-article:11421370pubmed:authorpubmed-author:MikhailN NNNlld:pubmed
pubmed-article:11421370pubmed:issnTypePrintlld:pubmed
pubmed-article:11421370pubmed:volume63lld:pubmed
pubmed-article:11421370pubmed:ownerNLMlld:pubmed
pubmed-article:11421370pubmed:authorsCompleteYlld:pubmed
pubmed-article:11421370pubmed:pagination236-41lld:pubmed
pubmed-article:11421370pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:meshHeadingpubmed-meshheading:11421370...lld:pubmed
pubmed-article:11421370pubmed:articleTitleHepatitis C in a community in Upper Egypt: I. Cross-sectional survey.lld:pubmed
pubmed-article:11421370pubmed:affiliationHepatitis C Prevention Project, Faculty of Medicine, Assiut University, Egypt.lld:pubmed
pubmed-article:11421370pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11421370pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11421370lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11421370lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11421370lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11421370lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11421370lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11421370lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11421370lld:pubmed